The world is seeing an unprecedented response to the pandemic by biotechnology researchers, emerging companies, and a wide range of pharmaceuticals. The results and the pace of innovation are not lost on investors anxious to see what new vaccines and treatments will emerge to address a disease…

While the world’s attention has been rightfully focused on the hope of a breakthrough that will eradicate COVID-19, the private biotech sector has racked up record-breaking investments during the first half of 2020. As much of the economy falls victim to the global threat, venture capital funding…

Since the earliest days of biotech, the UK and the USA have worked together to move science forward and build globally competitive companies.  James Watson (US) and Francis Crick (UK) worked together to solve the structure of the molecule that underpins the industry. The two technologies on which…

Day #2 of the BIO CEO & Investor Conference was all about the future. How can we ensure the workforce reflects the diverse demographics of the patients the industry serves? What does the future of biotech investment look like? How can we incentivize innovation? Here are some takeaways from …

Dr. Benjamin Cowen is the CEO of ImmunoMet, a clinical stage biotech company developing anti-tumor and immune-metabolism therapies. Holding both a PhD and an MBA, Cowen has worked across the spectrum of companies, including large pharma, mid-sized pharma and small venture-backed companies and his…

As a new college graduate in the early 80’s, Shawn Tomasello knew one thing for sure. She wanted a career in an industry that would constantly change; one that would keep her on her toes; allow her to always be learning.  At a career fair during her senior year, she discovered Pfizer Laboratories…

As more biotechnology executives begin to focus on strategies to diversify their boards to avoid groupthink and strengthen corporate governance, an emerging consensus is forming that initial public offerings are a key gateway to assembling higher-performing leadership teams. That was the unanimous…

As the biopharma industry has gained traction on new drug approvals throughout 2019, the financial dollars have followed suit.  According to BIO’s 2019 Emerging Therapeutic Company Trend Report, a record $17.5 billion in venture investment dollars went to emerging therapeutic companies globally in…

This year marked the first time BIO’s Start-Up Stadium was part of the BIO World Congress on Industrial Biotechnology and Agtech. The Shark Tank-style forum provided innovators across industrial biotech and agtech unparalleled access to key members of the investment community, venture philanthropy…

In a few short months BIO will be hosting the BIO Investor Forum (#BIF19) for the 17th time. The event’s long history is testament to the continued appetite for partnerships, collaborations and investment in the exciting world of early stage biotech companies on the cusp of medical breakthroughs…